> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves Roche Diagnostic for GSK’s Jemperil
- URL: https://www.fdaweb.com/fda-approves-roche-diagnostic-for-gsks-jemperil/
- Published: 2021-04-23T12:00:00.000Z
- Updated: 2026-09-14T16:56:09.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5149179

FDA has approved a Roche PMA for its Ventana MMR RxDx Panel, a companion diagnostic for qualifying patients for treatment with GlaxoSmithKline’s [just-approved](https://www.fdaweb.com/fda-approves-gsk-jemperli-for-some-endometrial-cancers/) Jemperli (dostarlimab-gxly) for advanced or recurrent endometrial cancer patients. The qualitative immunohistochemistry test is intended for use in assessing mismatch repair (MMR) proteins in formalin-fixed, paraffin-embedded endometrial carcinoma tissue by light microscopy.  
  
“MMR is a molecular mechanism that functions to correct certain errors that can spontaneously occur during DNA replication,” *the company says, adding that* MMR deficiency is most common in endometrial cancer.